Poolbeg Pharma PLC (POLB.L)
GBp 7.18
(-2.31%)
GBp 7.18
(-2.31%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | - | - | - |
| Cost of Revenue | 26 Thousand | 26 Thousand | 18 Thousand |
| Gross Profit | -26 Thousand | -26 Thousand | -18 Thousand |
| Operating Expenses | 5.03 Million | 4.98 Million | 2.33 Million |
| Selling, General and Administrative Expenses | 3.37 Million | 3.06 Million | 2.03 Million |
| Research and Development Expenses | 1.67 Million | 2.2 Million | 414 Thousand |
| Other Expenses | -14 Thousand | - | - |
| Cost and Expenses | 5.03 Million | 4.98 Million | 2.33 Million |
| Operating Income | -5.03 Million | -4.98 Million | -2.33 Million |
| Interest Expense | - | - | - |
| Income Tax Expense | -574 Thousand | -91 Thousand | 42 Thousand |
| Earnings before Tax | -4.5 Million | -4.77 Million | -2.33 Million |
| Net Income | -3.93 Million | -4.68 Million | -2.33 Million |
| Earnings Per Share Basic | -7.90 | -9.37 | -4.67 |
| Earnings Per Share Diluted | -7.86 | -9.37 | -4.67 |
| Weighted Average Shares Outstanding | 497.59 Thousand | 500 Thousand | 500 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 500 Thousand | 500 Thousand | 500 Thousand |
| Gross Margin | - | - | - |
| EBIT Margin | - | - | - |
| Profit Margin | - | - | - |
| EBITDA | -4.66 Million | -4.96 Million | -2.31 Million |
| Earnings Before Tax Margin | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 13 Thousand | - | 13 Thousand | 26 Thousand | - | 13 Thousand |
| Gross Profit | -13 Thousand | - | -13 Thousand | -26 Thousand | - | -13 Thousand |
| Operating Expenses | 1264.50 | 1264.50 | 2.79 Million | 5.01 Million | 1211.00 | 2.24 Million |
| Selling, General and Administrative Expenses | 1056.50 | 1056.50 | 1.96 Million | - | 990.50 | 1.38 Million |
| Research and Development Expenses | 350.50 | 350.50 | 812 Thousand | - | 406.00 | 865 Thousand |
| Other Expenses | -142.50 | -142.50 | -13 Thousand | -26 Thousand | - | - |
| Cost and Expenses | 1264.50 | 1264.50 | 2.79 Million | 5.04 Million | 1211.00 | 2.26 Million |
| Operating Income | -1264.50 | -1264.50 | -2.79 Million | -5.04 Million | -1478.00 | -2.26 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | 12.50 | 12.50 | -574 Thousand | -574 Thousand | 287.00 | - |
| Earnings before Tax | -1141.50 | -1141.50 | -2.69 Million | -4.5 Million | -1347.00 | -1.81 Million |
| Net Income | -1.12 Million | -1.12 Million | -2.12 Million | -3.93 Million | -1.06 Million | -1.81 Million |
| Earnings Per Share Basic | -2.26 | -0.00 | -4.30 | - | -0.00 | -3.62 |
| Earnings Per Share Diluted | -2.26 | -0.00 | -4.28 | - | -0.00 | -3.62 |
| Weighted Average Shares Outstanding | 500 Thousand | 500 Thousand | 492.79 Thousand | 500 Million | 492.79 Thousand | 500 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 500 Thousand | 500 Thousand | 495.18 Thousand | 500 Million | 495.18 Thousand | 500 Thousand |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -1258.00 | -1258.00 | -2.78 Million | - | -1295.00 | -2.24 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
API
FREKF
001270
HUI
MAPS
000565